Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis.
Sheedy, Kellen C; Camara, Maria I; Camacho, Pauline M.
; 21(3): 275-9, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25370317
Interventions for managing medication-related osteonecrosis of the jaw.
Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study.
Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis.
Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Osteoprotektivní lécba bisfosfonáty nebo denosumabem u nemocných s mnohocetným myelomem: prínos a rizika.
Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab.
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.
[Management of bone disease in myeloma patients: zoledronic acid or denosumab?].
Bisphosphonates and other bone agents for breast cancer.